Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has scheduled its first quarter 2025 earnings conference call for May 8, 2025, at 8 a.m. ET. The company will discuss financial results and operational highlights during the call.
U.S. participants can join by dialing 1-833-316-0545, while international callers should use 1-412-317-5726. A live webcast will be available, and a replay can be accessed through Intellia's website after 12 p.m. ET on the same day.
Intellia Therapeutics (NASDAQ:NTLA), un'azienda in fase clinica specializzata in terapie basate su CRISPR, ha programmato la conferenza telefonica per la presentazione dei risultati del primo trimestre 2025 per il 8 maggio 2025 alle 8:00 ET. Durante la chiamata verranno discussi i risultati finanziari e i principali aggiornamenti operativi.
I partecipanti negli Stati Uniti possono collegarsi chiamando il 1-833-316-0545, mentre i chiamanti internazionali devono utilizzare il numero 1-412-317-5726. Sarà disponibile una diretta web e la registrazione potrà essere consultata sul sito di Intellia dopo le 12:00 ET dello stesso giorno.
Intellia Therapeutics (NASDAQ:NTLA), una empresa en etapa clínica especializada en terapias basadas en CRISPR, ha programado su llamada de conferencia de resultados del primer trimestre de 2025 para el 8 de mayo de 2025 a las 8 a.m. ET. Durante la llamada se discutirán los resultados financieros y los aspectos operativos destacados.
Los participantes en EE.UU. pueden unirse marcando el 1-833-316-0545, mientras que los llamantes internacionales deben usar el 1-412-317-5726. Habrá una transmisión en vivo y una repetición estará disponible en el sitio web de Intellia después de las 12 p.m. ET del mismo día.
Intellia Therapeutics (NASDAQ:NTLA)는 CRISPR 기반 치료법에 특화된 임상 단계 유전자 편집 회사로, 2025년 5월 8일 오전 8시 ET에 2025년 1분기 실적 컨퍼런스 콜을 예정하고 있습니다. 통화 중에 재무 결과 및 운영 주요 내용을 논의할 예정입니다.
미국 참가자는 1-833-316-0545로 전화할 수 있으며, 해외 참가자는 1-412-317-5726를 이용해야 합니다. 생중계가 제공되며, 같은 날 오후 12시 ET 이후 Intellia 웹사이트에서 다시보기를 시청할 수 있습니다.
Intellia Therapeutics (NASDAQ:NTLA), une société en phase clinique spécialisée dans les thérapies basées sur CRISPR, a programmé sa conférence téléphonique pour les résultats du premier trimestre 2025 le 8 mai 2025 à 8h00 ET. La société discutera des résultats financiers et des points forts opérationnels lors de l’appel.
Les participants américains peuvent se joindre en composant le 1-833-316-0545, tandis que les appelants internationaux doivent utiliser le 1-412-317-5726. Une webdiffusion en direct sera disponible, et un replay pourra être consulté sur le site d’Intellia après 12h00 ET le même jour.
Intellia Therapeutics (NASDAQ:NTLA), ein klinisch tätiges Unternehmen für Gen-Editing mit Spezialisierung auf CRISPR-basierte Therapien, hat seine Telefonkonferenz zur Bekanntgabe der Ergebnisse für das erste Quartal 2025 für den 8. Mai 2025 um 8 Uhr ET angesetzt. Während des Calls werden finanzielle Ergebnisse und operative Highlights besprochen.
Teilnehmer aus den USA können unter der Nummer 1-833-316-0545 teilnehmen, internationale Anrufer verwenden bitte 1-412-317-5726. Ein Live-Webcast wird angeboten, und eine Aufzeichnung ist ab 12 Uhr ET am selben Tag auf der Webseite von Intellia verfügbar.
- None.
- None.
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on May 8, 2025, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
FAQ
When is Intellia Therapeutics (NTLA) Q1 2025 earnings call?
How can I join Intellia Therapeutics' Q1 2025 earnings call?
Where can I find the replay of NTLA's Q1 2025 earnings call?
What does Intellia Therapeutics (NTLA) specialize in?
